Get the Stockscreener App
29.72
0.00%
0.00
After Hours:
29.90
0.18
+0.61%
Arrowhead Pharmaceuticals Inc stock is traded at $29.72, with a volume of 3.04M.
It is up +0.00% in the last 24 hours and up +66.97% over the past month.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
See More
Previous Close:
$29.72
Open:
$29.65
24h Volume:
3.04M
Relative Volume:
1.38
Market Cap:
$4.11B
Revenue:
$181.74M
Net Income/Loss:
$-143.97M
P/E Ratio:
-21.38
EPS:
-1.39
Net Cash Flow:
$9.60M
1W Performance:
+2.22%
1M Performance:
+66.97%
6M Performance:
+88.46%
1Y Performance:
+46.87%
1-Day Range:
$29.51
$31.13
1-Week Range:
$27.10
$31.13
52-Week Range:
$9.57
$31.13
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Name
Arrowhead Pharmaceuticals Inc
Sector
Industry
Phone
626-696-4702
Address
177 E COLORADO BLVD, PASADENA, CA
Compare ARWR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
29.72 | 3.99B | 181.74M | -143.97M | 9.60M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-24 | Initiated | Goldman | Neutral |
| Dec-04-23 | Initiated | BofA Securities | Buy |
| Sep-19-23 | Initiated | Citigroup | Neutral |
| Jul-21-23 | Initiated | TD Cowen | Outperform |
| May-12-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Apr-26-23 | Initiated | SMBC Nikko | Outperform |
| Apr-12-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-11-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-19-22 | Resumed | Goldman | Buy |
| Aug-06-21 | Reiterated | Chardan Capital Markets | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-19-20 | Initiated | Citigroup | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| May-08-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-15-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-24-20 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Mar-17-20 | Initiated | Goldman | Neutral |
| Jan-21-20 | Initiated | SVB Leerink | Underperform |
| Dec-13-19 | Initiated | Oppenheimer | Perform |
| Nov-29-19 | Reiterated | Chardan Capital Markets | Buy |
| Nov-27-19 | Reiterated | B. Riley FBR | Buy |
| Nov-25-19 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-24-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-22-19 | Reiterated | Chardan Capital Markets | Buy |
| Oct-03-19 | Initiated | Robert W. Baird | Outperform |
| Sep-07-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| Sep-06-18 | Reiterated | Chardan Capital Markets | Buy |
| Aug-08-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Jul-02-18 | Reiterated | Chardan Capital Markets | Buy |
View All
Arrowhead Pharmaceuticals Inc Stock (ARWR) Latest News
H.C. Wainwright Reiterated a Buy on Arrowhead Pharmaceuticals (ARWR) - MSN
Corebridge Financial Inc. Sells 136,598 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead files to begin clinical trials of ARO-MAPT - BioWorld MedTech
Ionis, Arrowhead file dueling patent lawsuits over genetic-disorder drug - Reuters
Hsbc Holdings PLC Invests $173,000 in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals stock hits 52-week high at 29.35 USD By Investing.com - Investing.com Canada
Arrowhead Pharmaceuticals stock hits 52-week high at 29.35 USD - Investing.com
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by MetLife Investment Management LLC - MarketBeat
Arrowhead sues Ionis over patent dispute related to lead asset - Seeking Alpha
Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals - Business Wire
Zacks Small Cap Has Pessimistic View of ARWR FY2025 Earnings - MarketBeat
Arrowhead Pharmaceuticals at Morgan Stanley Conference: Strategic Growth and Partnerships - Investing.com Canada
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for - PharmiWeb.com
Arrowhead seeks approval for Alzheimer’s drug trial - Investing.com
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies - BioSpace
Arrowhead Pharmaceuticals : RNA Leaders USA 2025 CNS - MarketScreener
Arrowhead seeks approval to begin ARO-MAPT Alzheimer's trial - MarketScreener
Breakthrough Brain-Penetrating RNAi Drug: Arrowhead's New Alzheimer's Treatment Shows Promise in Primates - Stock Titan
Equities Analysts Set Expectations for ARWR FY2026 Earnings - MarketBeat
Arrowhead Pharmaceuticals at H.C. Wainwright: Strategic Growth and Pipeline Expansion - Investing.com Canada
Can Arrowhead Pharmaceuticals Inc. be recession proof2025 Macro Impact & Weekly Return Optimization Plans - Lancaster City Council
Transcript : Arrowhead Pharmaceuticals, Inc. Presents at H.C. Wainwright 27th Annual Global Investment Conference, Sep-09-2025 10 - MarketScreener
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Hits New 12-Month HighShould You Buy? - MarketBeat
Why Shares in Arrowhead Pharmaceuticals Surged on News of a Novartis Deal - AOL.com
Arrowhead Pharmaceuticals Shares Drop After Sarepta Sells Stake - MSN
Sentiment Turns Positive on Arrowhead Pharmaceuticals Inc. — Reversal Ahead2025 Valuation Update & Fast Entry High Yield Stock Tips - beatles.ru
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Earns "Buy" Rating from HC Wainwright - MarketBeat
The week in pharma: action, reaction and insight – week to September 5 - The Pharma Letter
ADAR1 Capital Management LLC Acquires 43,400 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals and Novartis sign global deal for siRNA therapy - MSN
Arrowhead Pharmaceuticals Inc. stock outlook for YEARPortfolio Performance Report & Long Hold Capital Preservation Plans - Newser
Arrowhead Pharmaceuticals Inc. stock trendline breakdownMarket Activity Summary & Weekly High Return Stock Forecasts - Newser
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Up 11%Still a Buy? - MarketBeat
Should value investors consider Arrowhead Pharmaceuticals Inc.Share Buyback & Weekly Top Gainers Alerts - خودرو بانک
Is Arrowhead Pharmaceuticals Inc. stock risky to hold now2025 Year in Review & High Accuracy Investment Signals - خودرو بانک
News impact scoring models applied to Arrowhead Pharmaceuticals Inc.July 2025 Catalysts & Free Safe Entry Trade Signal Reports - Newser
Can Arrowhead Pharmaceuticals Inc. grow without dilutionMarket Movers & Weekly Stock Performance Updates - خودرو بانک
Smart tools for monitoring Arrowhead Pharmaceuticals Inc.’s price action2025 Risk Factors & Consistent Growth Equity Picks - Newser
Arrowhead Pharmaceuticals at Cantor Global Healthcare Conference - AInvest
Transcript : Arrowhead Pharmaceuticals, Inc. Presents at Cantor Global Healthcare Conference 2025, Sep-04-2025 09 - MarketScreener
What is Arrowhead Pharmaceuticals Inc. s 5 year growth outlookTrade Signal Summary & Free Real-Time Volume Trigger Notifications - خودرو بانک
What’s next for Arrowhead Pharmaceuticals Inc. stock priceQuarterly Trade Review & Breakout Confirmation Trade Signals - Newser
Arrowhead Pharmaceuticals shares rise 3.82% intraday after insider sold shares. - AInvest
Identifying reversal signals in Arrowhead Pharmaceuticals Inc.2025 Fundamental Recap & Low Risk Growth Stock Ideas - Newser
Jim Cramer on Arrowhead Pharmaceuticals (ARWR): “It Doesn’t Make Any Money” - MSN
Magnetar Financial LLC Boosts Stock Position in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Will earnings trigger a reversal in Arrowhead Pharmaceuticals Inc.July 2025 Retail & Verified Momentum Watchlists - Newser
Using Python tools to backtest Arrowhead Pharmaceuticals Inc. strategiesPortfolio Risk Report & Real-Time Volume Spike Alerts - Newser
How to forecast Arrowhead Pharmaceuticals Inc. trends using time seriesQuarterly Market Review & Fast Gain Stock Trading Tips - Newser
Will Arrowhead Pharmaceuticals Inc. benefit from AI trendsJuly 2025 Big Picture & Real-Time Buy Signal Notifications - خودرو بانک
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Bought by Rafferty Asset Management LLC - MarketBeat
Arrowhead Pharmaceuticals Inc Stock (ARWR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):